25 August 2020
SPL7013 nasal spray for COVID-19 – development update
17 August 2020
Starpharma signs new DEP® partnership with Chase Sun
30 July 2020
DEP® docetaxel and gemcitabine combination trial commences
30 July 2020
Quarterly Cashflow and Activities Report
27 July 2020
AZD0466 trial opens MD Anderson Cancer Center as a site

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.